The development of Tigilanol Tiglate as a neo-adjuvant in immuno-oncology [ 2019 - ]

Research Grant

Researchers: Dr Glen Boyle (Principal investigator) ,  Dr Jason Cullen ,  Dr Paul Reddell ,  Prof Peter Parsons

Brief description Despite the progress made with new immunotherapies for treating metastatic cancer, lack of response in most patients remains a challenge. Our work with Tigilanol Tiglate (currently in human clinical trials as a locally-delivered treatment for a range of solid tumours) has shown that this agent can stimulate immune cell activity in non-responsive cancers. This project will extend the use of this drug, alone or in combination with other therapies, as a new option in treating metastatic cancers.

Funding Amount $657,521.00

Funding Scheme Development Grants

Notes Development Grant